西班牙语在线翻译：请输入需要翻译的西班牙语内容，可以实现西班牙语和32种语言的相互在线翻译，每次输入请不要超过320个字符，超过请分段翻译。
请输入或粘贴需要翻译的西班牙语文字：
只显示译文
显示原译文
【】 还能输入字
自动检测中英文
English(英语)");
中文(简体)
中文(繁體)
日本語(日语)
Fran?ais(法语)
Русский(俄语)
Deutsch(德语)
espa?ol(西班牙语)
português(葡萄牙语)
Italiano(意大利语)
?λληνα?(希腊语)
Hollands(荷兰语)
Svensk(瑞典语)
????? ???????(阿拉伯语)
?eské(捷克语)
Dansk(丹麦语)
Suomi(芬兰语)
Norske(挪威语)
България(保加利亚语)
???? ?????(波斯语)
Hausa(豪萨语)
?????(希伯来语)
????? ????(印地语)
A magyar(匈牙利语)
pushtu(普什图语)
Polski(波兰语)
Romania(罗马尼亚语)
Srbija(塞尔维亚语)
???????(泰语)
Türk(土耳其语)
????(乌尔都语)
中文(简体)
中文(繁體)
English(英语)
日本語(日语)
Fran?ais(法语)
Русский(俄语)
Deutsch(德语)
espa?ol(西班牙语)
português(葡萄牙语)
Italiano(意大利语)
?λληνα?(希腊语)
Hollands(荷兰语)
Svensk(瑞典语)
????? ???????(阿拉伯语)
?eské(捷克语)
Dansk(丹麦语)
Suomi(芬兰语)
Norske(挪威语)
България(保加利亚语)
???? ?????(波斯语)
Hausa(豪萨语)
?????(希伯来语)
????? ????(印地语)
A magyar(匈牙利语)
pushtu(普什图语)
Polski(波兰语)
Romania(罗马尼亚语)
Srbija(塞尔维亚语)
???????(泰语)
Türk(土耳其语)
????(乌尔都语)
* 点击翻译按钮即可获得西班牙语翻译结果，在结果框内点击鼠标右键可以全选并复制。
在线翻译二：请输入翻译内容，支持英语、日语、法语等在线翻译，翻译结果比较精准。
英语 → 中文简体（1）
英语 → 中文简体（2）
中文简体 → 英语（1）
中文简体 → 英语（2）
中文简体 → 日语（1）
中文简体 → 日语（2）
中文简体 → 法语（1）
中文简体 → 法语（2）
日语 → 中文简体（1）
日语 → 中文简体（2）
Example: Welcome to China
免费代码：复制以下代码到你的网站、博客等，可以实现强大的免费在线翻译功能。
&form name=&tranform& action=&http://en.httpcn.com/Translate_API.html&
method=&post& target=&_blank&&
&select size=&1& name=&lang&&
&option value=&01|en_cn& selected=&&&英语 → 中文简体（1）&/option&
&option value=&02|en_cn&&英语 → 中文简体（2）&/option&
&option value=&01|cn_en&&中文简体 → 英语（1）&/option&
&option value=&02|cn_en&&中文简体 → 英语（2）&/option&
&option value=&01|cn_ja&&中文简体 → 日语（1）&/option&
&option value=&02|cn_ja&&中文简体 → 日语（2）&/option&
&option value=&01|cn_fr&&中文简体 → 法语（1）&/option&
&option value=&02|cn_fr&&中文简体 → 法语（2）&/option&
&option value=&01|ja_cn&&日语 → 中文简体（1）&/option&
&option value=&02|ja_cn&&日语 → 中文简体（2）&/option&
&/select&&input type=&submit& value=&开始翻译& name=&sub1&&
&input type=&hidden& name=&start& value=&ok&&&br&
&textarea onfocus=&this.select()& name=&text& rows=&8& cols=&88&
style=&font-family:arial&&Example: Welcome to httpcn.com&/textarea&有道首页中英中法中韩中日中葡中德中西中俄
| 精选阅读必备课程折扣精选四六级考研GRE雅思实用英语加载中...当前位置：
&帮忙翻译一下呢！
帮忙翻译一下呢！
作者 wuhaofei2006
Lung Cancer Vaccine Enters Large-scale Clinical Trial
A new treatment for the most common form of lung cancer, developed from initial research by Cancer Research UK scientists, has entered a pivotal phase III clinical trial.
The drug, called Stimuvax, is a type of therapeutic vaccine that targets a specific protein found in many tumours, including non-small cell lung cancer. It was developed by Canadian biotech company Biomira following Cancer Research UK-funded studies led by Professor Joyce Taylor-Papadimitriou of Guy's Hospital, London. Biomira have already run phase II trials with very encouraging results.
The international phase III trial, named START (Stimulating Targeted Antigenic Responses To NSCLC), is expected to enrol its first patient this month. Run by pharmaceutical company Merck KGaA, it will eventually include more than 1,300 lung cancer patients in 30 countries, including the UK.
Therapeutic vaccines are a relatively new development in cancer treatment. Unlike preventative vaccines, they are treatments that induce the body's own immune system to identify and kill existing cancer cells. Stimuvax is designed to stimulate the immune system to recognise and react to a molecule called MUC1, which is much more abundant on tumour cells than healthy cells. The immune system then kills the cancer cells with MUC1, hopefully without overly harming healthy cells.
Cancer Research Technology Limited (CRT), Cancer Research UK's development and commercialisation company, licensed a number of discoveries to Biomira, which led to the development of Stimuvax for advanced non small cell lung cancer. Merck KGaA also plans to investigate the use of Stimuvax for other types of cancer.
Dr Keith Blundy, chief operating officer of CRT, said: &We are extremely pleased that Stimuvax has entered the final stage of clinical trials. The drug is one of CRT's portfolio of more than 20 partnered agents in clinical development. Targeted vaccines are an exciting approach that could potentially offer new treatment options for major types of cancer.&
Harpal Kumar, chief executive of CRT and chief operating officer of Cancer Research UK, said: &We're delighted that another drug based on Cancer Research UK-funded basic research has reached the final stage of clinical development. The 'translation' of basic research into patient benefit is the major focus of our work and we hope that new ventures, such as the expansion of our drug discovery activities across the country, will lead to many more such drugs entering trials in the future.&
Lung cancer
-- Lung cancer is the second most common cancer in the UK after breast cancer, and the most common cancer worldwide.
-- There were more than 37,000 cases of lung cancer diagnosed in the UK in 2003.
-- Non small cell lung cancer accounts for 80 per cent of total lung cancer cases.
-- Current standard treatments for lung cancer patients are surgery, platinum-based combination chemotherapy and radiotherapy.
START trial
In the trials, Stimuvax will be compared to a placebo. More information on the START trial can be found here.
Research centres in Edinburgh, Leeds and Exeter will be participating in the trial.
For more information about clinical trials in the UK, visit Cancer Research UK's patient information website, CancerHelp UK.
Cancer Research Technology
Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found here.
About Cancer Research UK
Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
-- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
-- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
-- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
-- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.
Lung Cancer Vaccine Enters Large-scale Clinical Trial
肺癌疫苗研究进入大规模临床研究阶段
A new treatment for the most common form of lung cancer, developed from initial research by Cancer Research UK scientists, has entered a pivotal phase III clinical trial.
最常见的癌症治疗的新药物已进入了III临床研究的关键阶段，该药物是由英国癌症科学家最开始研究的。
The drug, called Stimuvax, is a type of therapeutic vaccine that targets a specific protein&&found in many tumours, including non-small cell lung cancer. It was developed by Canadian biotech company Biomira following Cancer Research UK-funded studies led by Professor Joyce Taylor-Papadimitriou of Guy's Hospital, London. Biomira have already run phase II trials with very encouraging results.
Stimuvax是一种治疗性疫苗，作用靶位是包括非小细胞癌症许多肿瘤中发现的一种特殊蛋白。它是由加拿大生物科技公司BIOMIRA应英国伦敦GUY医院教授Joyce Taylor-Papadimitriou领头的英国癌症研究资助的研究而研发的。Stimuvax II临床已经完成，并取得了可喜的结果。
The international phase III trial, named START (Stimulating Targeted Antigenic Responses To NSCLC), is expected to enrol its first patient this month. Run by pharmaceutical company Merck KGaA, it will eventually include more than 1,300 lung cancer patients in 30 countries, including the UK.
被称做START（对非小细胞肺癌的刺激靶向抗原响应）III临床研究应该将该月治疗的第一例病人做登记。Merck KGaA 制药公司进行的研究最终将涉及包括英国在内的30个国家的1300多癌症病人。
Therapeutic vaccines are a relatively new development in cancer treatment. Unlike preventative vaccines, they are treatments that induce the body's own immune system to identify and kill existing cancer cells. Stimuvax is designed to stimulate the immune system to recognise and react to a molecule called MUC1, which is much more abundant on tumour cells than healthy cells. The immune system then kills the cancer cells with MUC1, hopefully without overly harming healthy cells.
治疗性疫苗是一种相对新的癌症治疗方法。不象预防性疫苗，治疗性疫苗是使自身免疫系统识别并杀死癌症细胞。Stimuvax设计思路是刺激免疫系统识别被称为MUC1的分子并对其做出反应，然后免疫系统将杀死含有MUC1分子的癌症细胞，希望不会过度杀害正常细胞。MUC1在肿瘤细胞要比正常细胞上多。
Cancer Research Technology Limited (CRT), Cancer Research UK's development and commercialisation company, licensed a number of discoveries to Biomira, which led to the development of Stimuvax for advanced non small cell lung cancer. Merck KGaA also plans to investigate the use of Stimuvax for other types of cancer.
癌症研究技术有限、英国癌症研究发展和商业公司注册了到BIOBIRA许多发现，这使得Stimuvax发展成为非小细胞肺癌的晚期治疗药。Merck KgaA 公司也计划调研Stimuvax治疗其它类型的癌症使用情况。
Dr Keith Blundy, chief operating officer of CRT, said: &We are extremely pleased that Stimuvax has entered the final stage of clinical trials. The drug is one of CRT's portfolio of more than 20 partnered agents in clinical development. Targeted vaccines are an exciting approach that could potentially offer new treatment options for major types of cancer.&
CRT公司经营主管Keith Blundy 博士称：“我们很高兴Stimuvax进入临床研究的最后阶段。&&该药是CRT公司临床研究的20多种中重要的药物之一。靶位疫苗是一种鼓舞人心的治疗方法，该治疗方法有为主要类型的癌症提供新治疗方法的潜力。
Harpal Kumar, chief executive of CRT and chief operating officer of Cancer Research UK, said: &We're delighted that another drug based on Cancer Research UK-funded basic research has reached the final stage of clinical development. The 'translation' of basic research into patient benefit is the major focus of our work and we hope that new ventures, such as the expansion of our drug discovery activities across the country, will lead to many more such drugs entering trials in the future.&
CRT的CEO兼英国癌症研究的经营主管Harpal Kumar称：“很高兴基于英国癌症研究资助的基础研究的另一药物近入了临床研究的最后阶段，我们现在关注的是将基础研究转化为病人受益，我们希望如全国范围内的药物研究这样的新尝试在将来将会使更多药物进入研究阶段。”
Lung cancer
-- Lung cancer is the second most common cancer in the UK after breast cancer, and the most common cancer worldwide.
--在英国肺癌是继乳腺癌之后的第二常见癌症，是世界上最常见的癌症
-- There were more than 37,000 cases of lung cancer diagnosed in the UK in 2003.
2003年英国被确诊为肺癌的超过37000例。
-- Non small cell lung cancer accounts for 80 per cent of total lung cancer cases.
--非小细胞肺癌在肺癌中占80%。
--Current standard treatments for lung cancer patients are surgery, platinum-based combination chemotherapy and radiotherapy.
--肺癌当前的标准治疗方法有手术、基于铂的化学和放射联合疗法。
START trial
START 研究
In the trials, Stimuvax will be compared to a placebo. More information on the START trial can be found here.
在临床研究中，Stimuvax将与安慰剂做对比。关于START 研究的更多信息将可以在这里看到。
Research centres in Edinburgh, Leeds and Exeter will be participating in the trial.
研究中心设在爱丁堡，利兹和埃克塞特也将参与。
For more information about clinical trials in the UK, visit Cancer Research UK's patient information website, CancerHelp UK.
英国临床研究的更多信息请参看英国癌症病人癌症研究信息网-英国癌症救助。
Cancer Research Technology
癌症研究技术
Cancer Research Technology Limited (CRT) is a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. Further information about CRT can be found here.
癌症研究技术有限公司（CRT）是一家专业的商业开发公司，其宗旨是在癌症研究中作出有益于病人的新发现。CRT与领先的世界癌症科学家及其机构密切合作，以保护研究中出现的知识产权问题及与商业合作者建立联系。CRT推动癌症新的治疗方法、疫苗、诊断学及可行性技术的发现、研发及市场化。CRT是由世界最大的独立的癌症研究基金-英国癌症研究-完全所有。
About Cancer Research UK
英国癌症研究
Together with its partners and supporters, Cancer Research UK's vision is to beat cancer.
英国癌症研究和其合作者及支持者的目标是战胜癌症。
-- Cancer Research UK carries out world-class research to improve understanding of the disease and find out how to prevent, diagnose and treat different kinds of cancer.
--英国癌症研究开展世界级的研究，以提高对各种癌症的认识，并寻找预防、诊断及治疗方法。
-- Cancer Research UK ensures that its findings are used to improve the lives of all cancer patients.
--英国癌症研究确定研究结果用于提高所有癌症病人的生命。
-- Cancer Research UK helps people to understand cancer, the progress that is being made and the choices each person can make.
--英国癌症研究帮助人们认识癌症、病变进程及帮助人们做出选择。
-- Cancer Research UK works in partnership with others to achieve the greatest impact in the global fight against cancer.
--英国癌症研究和其它合作者在全球抗癌中取得了重大影响。
可以的话别忘给鼓励呀 ，
可惜我都翻译完了呢！
楼上的厉害啊！！！！
2 楼的既然翻译完了，看我翻译有什么不对的地方，请多指教！
楼上的MM好热心 鼓励,,,,,,,,,,,
我加你QQ了
24小时热帖
下载小木虫APP
与700万科研达人随时交流《翻译一下 Translate it》是一款语音翻译，语音识别和翻译都是借用 Google 的服务，整合得很不错。出国旅游？不懂外语？用翻译一下 Translate it 解决困扰，只需要双击电源键并说话。29种语言互相翻译，几秒便可获得。
手机扫描二维码下载
大家都在玩
大小：13.9M
让您的App说话!如果您口袋里有这么一个具有多重语言又会发音、包含25种语言超过110...
大小：5.8M
★ 免费翻译任何文本!★ 一个翻译38种语言的完美工具!★没有限制和额外支付的费...
这款应用收集了众多的迈克尔杰克逊的壁纸，通过个性化的设置，使您的手机桌面看起...
大小：1.83MB
所有的语言翻译应用程序让你翻译一下你在超过80种语言说。产品特点：零翻译费用，...
大小：4.11 MB
Google翻译是Google基于Androi...
大小：8.52MB
想象一下，自己在沟通的地方不是他们的母语。现在想想，很轻松就好像有一个应用程...
大小：3.4MB
强大、优雅、高效集成翻译，语音，词典，Wiki，对话等实用功能。优化使用Google、B...
大小：2.91MB
收到一份重要的外语文件，你会通过什么方式来了解里面的信息？通过谷歌在线翻译，...
大小：1.52MB
大小：4.33MB
《翻译一下 Translate it》是一款语音翻译，语音识别和翻译都是借用 Google 的...
大小：5.92MB
Google翻译是Google基于Android平台开发的功能强大的在线翻译软件，支持超过50种不...
大小：2.2MB
是最好的日语翻译应用软件。向在学日语的人推荐。特長1：能快速有效的翻译特長2：...
大小：2.01MB
一个有信仰的泰语翻译应用。使用全新领先的翻译引擎，让翻译变得更快更可靠啊萨瓦...
大小：2.17MB
使用有道翻译 api 的简易翻译工具。看心情增加更多 api 支持(计划增加百度翻译...
大小：2.1MB
所有的语言翻译应用程序让你翻译一下你在超过80种语言说。 产品特点：- 零翻译费...
大小：1.39MB
使用有道翻译 api 的简易翻译工具。看心情增加更多 api 支持(计划增加百度翻译...
大小：1.83MB
使用有道翻译 api 的简易翻译工具。看心情增加更多 api 支持(计划增加百度翻译...
大小：1.84MB
使用有道翻译 api 的简易翻译工具。看心情增加更多 api 支持(计划增加百度翻译...
大小：1.84MB
使用有道翻译 api 的简易翻译工具。看心情增加更多 api 支持(计划增加百度翻译...
大小：2.01MB
一个有信仰的泰语翻译应用。使用全新领先的翻译引擎，让翻译变得更快更可靠啊萨瓦...
大家都在玩
热门安卓应用
WiFi万能钥匙
百度输入法
搜狗输入法
其他用户正在浏览
猪猪保卫战
蘑菇园 官方中文版